Today is: April 13, 2011

Evaluate Your Case Today

Calcagno & Associates

900 South Avenue, 3rd Floor
Staten Island, NY, 10314
Phone: 1-800-WE-FIGHT
             (718) 568-3585

By appointment only

Battery Place
New York, NY, 10004
Phone: (800) 933-4448

Grand Concourse Bronx, NY, 10451 Phone: (718) 933-4448

Bay Parkway Brooklyn, NY, 11214 Phone: (800) 487-6837

Name (First & Last)
DOB (Victims Date of Birth)


Email Address





Message about your case


Fosamax Linked to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a medication prescribed to treat osteoporosis and prevent bone loss and fractures in postmenopausal women. It is also prescribed to treat Paget’s disease. Fosamax also comes in Fosamax Plus D (alendronate sodium/ cholecalciferol). Fosamax was approved in 1995 and is manufactured by Merck.

Fosamax Patients Have Legal Rights

What are the side effects associated with Fosamax?

While Merck warns of gastrointestinal (espophagus and stomach) problems including heartburn, ulceration, scarring, and inflammation, it has failed to warn of other serious side effects associated with Fosamax.

Fosamax & Osteonecrosis of the Jawbone (ONJ)

Fosamax has been linked with Osteonecrosis of the Jawbone. Osteonecrosis refers to death of a bone; the bone tissue rots and dies due to lack of blood supply. In Osteonecrosis of the Jawbone, parts of the jaw bone rot and may fail to heal following oral surgery or dental work. Patients taking Fosamax are at a higher risk for developing Osteonecrosis of the Jawbone.

Fosamax & Arrythmia

A study of 8,000 women published in the New England Journal of Medicine in May 2007 indicated that one bisphosphonate, Zometa, increased the risk for serious heartbeat irregularity. Merck’s Fosamax study from 1997 also suggested an increased risk of atrial fibrillation.

Return to Defective Drugs Listing


Keywords | Articles | Locations | Coupons |